Thomas Steyer’s Ionis Pharmaceuticals IONS Stock Holding History

Thomas Steyer’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,800	Closed	-$360K	–	137
2026 Q1	$360K	Hold	4,800	–	–	﹤0.01%	112
2025 Q4	$380K	Hold	4,800	–	–	﹤0.01%	101
2025 Q3	$314K	Buy	+4,800	New	+$234K	﹤0.01%	102
2024 Q3	–	Sell	-4,800	Closed	-$229K	–	170
2024 Q2	$229K	Sell	4,800 -729,200	-99%	-$29.9M	﹤0.01%	129
2024 Q1	$31.8M	Sell	734,000 -821,020	-53%	-$39.1M	0.14%	63
2023 Q4	$78.7M	Buy	1,555,020 +828,020	+114%	+$39.7M	0.36%	51
2023 Q3	$33M	Buy	727,000 +722,000	+14,440%	+$29.8M	0.15%	69
2023 Q2	$205K	Buy	+5,000	New	+$192K	﹤0.01%	137
2021 Q2	–	Sell	-630,500	Closed	-$28.3M	–	308
2021 Q1	$28.3M	Sell	630,500 -119,500	-16%	-$6.66M	0.14%	90
2020 Q4	$42.4M	Buy	+750,000	New	+$37.4M	0.26%	70
2018 Q1	–	Sell	-645,000	Closed	-$32.4M	–	96
2017 Q4	$32.4M	Buy	645,000 +195,000	+43%	+$10.7M	0.26%	49
2017 Q3	$22.8M	Buy	+450,000	New	+$23.6M	0.2%	53

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Thomas Steyer's IONS Position: Q2 2026 in Review

Thomas Steyer sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 4,800 shares — an estimated $360K sold.

Thomas Steyer first reported a position in IONS in Q3 2017 and held it in 12 quarters. The position peaked at $78.7M in Q4 2023. 510 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Thomas Steyer reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 4,800 Ionis Pharmaceuticals shares in Q2 2026, an estimated $360K.
Thomas Steyer first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Thomas Steyer's Ionis Pharmaceuticals position peaked at $78.7M in Q4 2023.
510 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.